The M. Behçet is a chronic, recurrent inflammation of the classic triad of iritis (eye inflammation) and ulcerative mucosal lesions (ulcers) in the mouth and on the sexual organs.
The origin of the M. Behçet is as yet unclear.
A connection to genetic factors is described (HLA-B5-genotype). A family history is. Infections are assumed to be possible triggers.
The disease is expressed in a presumably by immune complexes mediated inflammation of small blood vessels (vasculitis), primarily of the venous system and deposition of inflammatory proteins and autoantibodies against the oral mucosa.
The M. Behçet is an extremely rare disease of young adults ages in Europe. In the eastern Mediterranean countries and in Japan it is more often found. In Turkey, a prevalence (frequency) was found up to 19/5131 population> 10 years. Males are affected slightly more often.
The diagnosis of M. Behçet is based on the characteristic symptoms. (Diagnostic criteria of the Behcet Syndrome Research Committee of Japan 1972)
The treatment of M. Behçet consists of the administration of cortisone. In particular, the aphthous ulcers talk to the administration of thalidomide good. Furthermore, in the treatment and colchicine, cyclosporin A, are cyclophosphamide, azathioprine, chlorambucil, applied IFN-alpha and plasmapheresis.